Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?

As the global health landscape shifts toward obesity treatments, investors are weighing the rapid growth of Novo Nordisk A/S (NYSE:NVO) against the deep-rooted stability of Pfizer Inc. (NYSE:PFE) to determine the better long-term choice.

Novo Nordisk has become a household name through its dominant position in medications for weight loss and diabetes. Pfizer operates as a diversified biopharmaceutical powerhouse with a massive portfolio of vaccines and medicines. Both companies are at a crossroads, making this a classic match-up between high-growth focus and broad-market value.

The case for Novo Nordisk A/S

Novo Nordisk focuses its business strategy on treating serious chronic diseases, particularly diabetes and obesity. It markets its products in roughly 170 countries and relies on a massive global workforce of nearly 70,000 employees. The company is currently shifting heavily into its GLP-1 portfolio, which serves a rapidly expanding global patient base.

In the 12 months ended Sept. 30, 2026, revenue reached around $49.3 billion, representing growth of approximately 5.7% compared to the prior period. Net income for this time was about $16.7 billion, which resulted in a strong net margin of roughly 34%. This performance highlights the company's ability to maintain high profitability within the competitive pharmaceutical stocks landscape.

As of its December 2025 balance sheet, the debt-to-equity ratio is approximately 0.7x. This metric, which measures total debt against shareholder equity, suggests a manageable debt load. Its current ratio, which measures the ability to cover short-term liabilities with short-term assets, is roughly 0.8x. In the fiscal year ended Dec. 31, 2025, free cash flow was about $4.3 billion, representing the cash remaining after the company pays for its operations and capital expenditures.

The case for Pfizer Inc.

Pfizer operates as a diversified biopharmaceutical giant that manages everything from drug discovery to global distribution. Its business relies on a complex network of managed care organizations and pharmacy benefit managers, which often exert significant pricing pressure on its products. In its latest annual report, the company noted that government-mandated price negotiations, especially for major products like Eliquis, impact its revenue.

In the 12 months ended Sept. 27, 2026, revenue reached approximately $63.6 billion. This reflected a growth rate of close to 1.3% over the preceding 12-month period. Net income was roughly $4.0 billion, which indicates a net margin of approximately 6.3%. This is a notable decrease from previous years as the company navigates a post-pandemic product environment.

As of the December 2025 balance sheet, Pfizer carries a debt-to-equity ratio of approximately 0.8x. This level of total debt relative to shareholders' equity is comparable to that of many of its industry peers. Its current ratio is roughly 1.2x, suggesting a solid cushion for meeting short-term financial obligations. In the fiscal year ended Dec. 31, 2025, free cash flow reached around $9.1 billion, providing substantial capital for dividends and reinvestment.

Risk profile comparison

Novo Nordisk faces significant risks related to the intense competition in the weight-loss market. As more players like Eli Lilly & Co. (NYSE:LLY) enter the GLP-1 space, the company may experience pricing pressure that could impact its high net margin. Additionally, manufacturing constraints for its most popular drugs could limit its ability to meet global demand, potentially handing market share to rivals.

Pfizer deals with intense pricing and reimbursement pressures from both government entities and private payers, exacerbated by recent legislative changes. The company also faces a significant threat from generic and biosimilar launches, such as those from Hikma Pharmaceuticals (OTC:HKMPF), which could erode revenue between 2026 and 2030. Furthermore, the company must successfully integrate major acquisitions while managing ongoing legal challenges related to product liability.

Valuation comparison

Pfizer appears to be the more affordable option based on its lower Forward P/E and P/S ratio, while Novo Nordisk carries a premium for its growth.

Valuation metrics include those sourced from Financial Modeling Prep (FMP) and may differ from those of other data providers.

Which stock would I buy for 2027?

Novo Nordisk has the blockbuster drugs Wegovy and Ozempic (the same drug marketed for different purposes), but faces investor doubts about its market position given a deal with the federal government to lower prices for the GLP-1s, the emergence of generic competitors, and the apparent advances by Eli Lilly in developing weight loss drugs expected to be superior to Novo's offerings.

Still, the introduction of the once-a-day Wegovy pill in the U.S. has been a resounding success, and the business has a patent on injectable Ozempic/Wegovy till 2032, providing it some competitive moat. Still, Wall Street sees sales declining by about 3% in fiscal 2026, with net income contracting by 4% as pricing pressures erode margins slightly. Long-term, analysts expect the company to reverse the 2026 decline and start growing again as new products come online.

Meanwhile, Pfizer isn't a hot growth stock, but it's also one of the giants of the pharmaceutical industry.

The company had a post-COVID-19 letdown of sorts, as pandemic-related demand ebbed, but the business has been flexing its might this year. In its first quarter of this year, Pfizer beat Wall Street analysts' expectations on sales and net income. That is partly because Pfizer has been buying growth -- it recently acquired oncology specialist Seagen and posted 20% growth in that business's products.

Pfizer is also allocating significant resources to new drug development, with 20 drug development starts scheduled for 2026 and eight data readouts expected, which report on the progress of treatments in development. After falling behind in the GLP-1 weight-loss drug market, Pfizer is also making strides toward becoming a competitor, with very positive Phase II (of III) trial results for an injectable GLP-1 reported earlier this year.

For the current fiscal year, Pfizer revenue is seen slumping slightly to $62.2 billion, while net income is seen rising $1.2 billion to $8.9 billion

Both are pharma giants under some pressure this year. Pfizer has the larger war chest of the two, with $14.3 billion in cash, compared to $6.8 billion for Novo Nordisk. Add that to its cheaper valuation, and Pfizer is the better turnaround bet for 2027.

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly, Novo Nordisk, and Pfizer. The Motley Fool recommends Hikma Pharmaceuticals Plc. The Motley Fool has a disclosure policy.